Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Publishes Data on microRNA-Based Lung Cancer Assay

Premium

Rosetta Genomics has published data validating its miRview Lung assay as a means to differentiate between the four main types of lung cancer.

The report appeared online last week in the Journal of Molecular Diagnostics.

The assay is based on the expression levels of eight microRNAs, measured using a quantitative RT-PCR platform.

In the study, the assay was validated on an independent set of 451 samples, more than half of which were pre-operative cytologic samples obtained as fine-needle aspirations or bronchial brushings and washings, Rosetta said.

More than 90 percent of the samples were successfully processed with an overall accuracy of 94 percent — a finding obtained with both pathologic and cytologic samples, which Rosetta said demonstrates the assay's ability to differentiate between squamous cell carcinoma, non-squamous non-small cell lung cancer, carcinoid, and small cell carcinoma.

The publication comes on the heels of the New York State Department of Health's conditional approval of miRview Lung (GWDN 6/26/2012).

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.